This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Experts urge early detection & better access to care
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Overall investment in the US facility is estimated around US$50 million
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide
There are 38.4 million people with diabetes in the United States
Metropolis Clinical Pathology will acquire and operate all laboratories and collection centers of Scientific Pathology in Agra and neighbouring towns through a slump sale transaction
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
Subscribe To Our Newsletter & Stay Updated
